Improving CAR T cell therapy by optimizing critical quality attributes.
Semin Hematol
; 57(2): 33-38, 2020 04.
Article
em En
| MEDLINE
| ID: mdl-32892841
ABSTRACT
Whether as a cure or bridge to transplant, chimeric antigen receptor (CAR)-T cell therapies have shown dramatic outcomes for the treatment of hematologic malignancies, and particularly relapsed/refractory B cell leukemia and lymphoma. However, these therapies are not effective for all patients, and are not without toxicities. The challenge now is to optimize these products and their manufacture. The manufacturing process is complex and subject to numerous variabilities at each step. These variabilities can affect the critical quality attributes of the final product, and this can ultimately impact clinical outcomes. This review will focus on optimizing the manufacturing variables that can impact the safety, purity, potency, consistency and durability of CAR-T cells.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos de Linfócitos T
/
Imunoterapia Adotiva
/
Neoplasias Hematológicas
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article